Extension Study of Participants From SPG302-ALS-001

PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 29, 2025

Primary Completion Date

May 30, 2026

Study Completion Date

August 31, 2026

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG

SPG302

Open label SPG302 to be self-administered daily by eligible participants for 52 weeks.

Trial Locations (3)

Macquarie University, North Ryde

Royal Brisbane and Women's Hospital, Herston

Flinders Medical Center, Adelaide